KRAS was differentially expressed between cell clusters from matched scRNA-seq data (maximum log-transformed fold change (logFC) = 0.346, q < 0.05; Fig. 4b), and immunohistochemistry for KRAS both in tissue from the primary patient and in PDX tissue corroborated a punctate pattern of expression across spatially separated regions within tumour sections (Fig. 4c). Here, KRAS is linked to neoplasm.